Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M73.5Revenue (TTM) $M15.0Net Margin (%)38.9Altman Z-Score4.4
Enterprise Value $M63.8EPS (TTM) $2.5Operating Margin %39.0Piotroski F-Score7
P/E(ttm)14.3Beneish M-Score-2.6Pre-tax Margin (%)38.9Higher ROA y-yY
Price/Book17.110-y EBITDA Growth Rate %--Quick Ratio3.1Cash flow > EarningsY
Price/Sales5.25-y EBITDA Growth Rate %-23.7Current Ratio3.1Lower Leverage y-yY
Price/Free Cash Flow12.5y-y EBITDA Growth Rate %--ROA % (ttm)100Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M2.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OPNT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

OPNT is held by these investors:



OPNT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sinclair MichaelExecutive Chairman, 10% Owner 2017-01-17Buy3,500$7.01409.27view
CRYSTAL ROGERCEO, 10% Owner 2017-01-17Buy3,475$6.99410.73view
Pollack KevinSee Remarks 2017-01-13Buy4,820$6.98411.46view
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.5920view
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.5920view

Press Releases about OPNT :

Quarterly/Annual Reports about OPNT:

News about OPNT:

Articles On GuruFocus.com
Opiant Pharmaceuticals, Inc. Provides an Update on NARCAN® Nasal Spray Sep 15 2017 
Opiant Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 19th Annual Global Investment Confer Sep 06 2017 
Opiant Pharmaceuticals, Inc. Announces Appointment of David O’Toole as Chief Financial Officer Sep 05 2017 
Opiant Pharmaceuticals, Inc. Announces Listing on the Nasdaq Capital Market Aug 28 2017 
Opiant CEO Roger Crystal Appears on Fox News Channel to Discuss the Opioid Crisis Being Declared a N Aug 14 2017 
Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Aug 10 2017 
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent Aug 04 2017 
Opiant CEO Roger Crystal Appears on Fox Business Network Jul 26 2017 
Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development for the Treatment of Jul 19 2017 
Opiant Pharmaceuticals, Inc. Announces Results of Positron Emission Tomography (PET) Study of Naloxo Mar 27 2017 

More From Other Websites
OPNT: Estimating When Royalties to NARCAN® Nasal Spray Revert Back to Opiant Sep 19 2017
Corporate News Blog - Opiant Delivers Update on NARCAN Nasal Spray; Surpasses $25 Million Net Sales... Sep 18 2017
Opiant Pharmaceuticals, Inc. Provides an Update on NARCAN® Nasal Spray Sep 15 2017
Opiant Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 19th Annual Global Investment... Sep 06 2017
Opiant Pharmaceuticals, Inc. Announces Appointment of David O’Toole as Chief Financial Officer Sep 05 2017
Opiant Pharmaceuticals, Inc. Announces Listing on the Nasdaq Capital Market Aug 28 2017
Opiant CEO Roger Crystal Appears on Fox News Channel to Discuss the Opioid Crisis Being Declared a... Aug 14 2017
OPNT: Receives Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization Aug 10 2017
Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray... Aug 10 2017
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent Aug 04 2017
Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions Jul 28 2017
Opiant CEO Roger Crystal Appears on Fox & Friends Jul 27 2017
Opiant CEO Roger Crystal Appears on Fox Business Network Jul 26 2017
OPNT: Encouraging Data From P1 Study of OPNT002 in Alcohol Use Disorder Jul 19 2017
Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development for the Treatment of... Jul 19 2017
Opiant Pharmaceuticals, Inc. Licenses Aegis Therapeutics’ Intravail® Drug Delivery Technology Jun 28 2017
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q3, 2017 By the Numbers : June 15, 2017 Jun 15 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}